血浆 DNA 甲基化分析用于肺腺癌的早期诊断。
DNA methylation analysis in plasma for early diagnosis in lung adenocarcinoma.
发表日期:2024 Jul 12
作者:
Yulin Jin, Rongguo Lu, Feng Liu, Guanyu Jiang, Ruixin Wang, Mingfeng Zheng
来源:
GENES & DEVELOPMENT
摘要:
肺腺癌(LUAD)是最常见的肺癌类型。 SHOX2和RASSF1A甲基化已被确定为肺癌诊断和预后的重要生物标志物。支气管肺泡灌洗液(BALF)在诊断肺部疾病方面表现出良好的特异性和敏感性,但其获取具有挑战性,可能会给患者带来不适。临床上,血浆样本比BALF更方便获取;然而,同时检测血浆中SHOX2和RASSF1A甲基化的研究很少。本研究旨在使用血浆样本评估 SHOX2 和 RASSF1A 联合启动子甲基化检测对早期 LUAD 的诊断价值。 BALF 和血液样本取自 36 名早期 LUAD 患者,对照组包括 19 名非肿瘤患者个人。采用人SHOX2和RASSF1A基因甲基化试剂盒评估所有受试者SHOX2和RASSF1A启动子甲基化水平。血浆中SHOX2和RASSF1A甲基化检出率为61.11%,略低于BALF(66.7%)。卡方检验显示BALF与血浆甲基化率差异无统计学意义(P>0.05)。血液的受试者工作特征 (ROC) 曲线下面积为 0.806(95% CI,0.677 至 0.900),而 BALF 为 0.781(95% CI,0.649 至 0.881)。此外,我们还分析了血浆中SHOX2和RASSF1A甲基化水平与性别、年龄、肿瘤分化、病理分类和其他临床病理变量的相关性;然而,没有观察到显着的相关性。通过使用血浆替代 BALF 样本,测量 SHOX2 和 RASSF1A 甲基化以实现 LUAD 的早期诊断,具有高灵敏度和特异性。版权所有 © 2024 作者。由 Wolters Kluwer Health, Inc. 出版
Lung adenocarcinoma (LUAD) represents the most prevalent type of lung cancer. SHOX2 and RASSF1A methylation have been identified as important biomarkers for diagnosis and prognosis of lung cancer. Bronchoalveolar lavage fluid (BALF) exhibits good specificity and sensitivity in diagnosing pulmonary diseases, but its acquisition is challenging and may cause discomfort to patients. In clinical, plasma samples are more convenient to obtain than BALF; however, there is little research on the concurrent detection of SHOX2 and RASSF1A methylation in plasma. This study aims to assess the diagnostic value of a combined promoter methylation assay for SHOX2 and RASSF1A in early-stage LUAD using plasma samples.BALF and blood samples were obtained from 36 early-stage LUAD patients, with a control group of nineteen non-tumor individuals. The promoter methylation levels of SHOX2 and RASSF1A in all subjects were assessed using the human SHOX2 and RASSF1A gene methylation kit.The methylation detection rate of SHOX2 and RASSF1A in plasma was 61.11%, slightly lower than that in BALF (66.7%). The Chi-square test revealed no significant difference in the methylation rate between BALF and plasma (P > 0.05). The area under the receiver operating characteristic (ROC) curve analysis for blood was 0.806 (95% CI, 0.677 to 0.900), while for BALF it was 0.781 (95% CI, 0.649 to 0.881). Additionally, we conducted an analysis on the correlation between SHOX2 and RASSF1A methylation levels in plasma with gender, age, tumor differentiation, pathologic classification, and other clinicopathological variables; however, no significant correlations were observed.Measurement of SHOX2 and RASSF1A methylation for early diagnosis of LUAD can be achieved with high sensitivity and specificity by using plasma as a substitute for BALF samples.Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.